Cytonus expands its Scientific Advisory Board with mRNA expert Michael...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

ACTS LAW Addresses Federal Correctional Institution in Dublin Controversy • Orion S.A. Earns Platinum Sustainability Rating by EcoVadis • NICOLE ARI PARKER IS THE FACE OF KAREN MILLEN'S ICONS SERIES VOL. 6 • Arcosa Publishes 2023 Sustainability Report • Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business • Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as Sustainability, Decarbo • Motlow State Community College Expands Accessibility With the Addition of YuJa Panorama Digital Accessibility Platform to Its Ed • Wounded Warrior Project, White House Celebrate and Honor Warriors at Annual Soldier Ride • The Birches at Concord Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • Ouro Teams Up with Texas One Fund with Multi-Year NIL X World Wallet Financial Empowerment Program for University of Texas Stude • Bay Square at Yarmouth Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada • CUPE BC, province’s largest union, kicks off convention in Vancouver • Voices for Humanity Bears Witness to Panama's Moral Resurgence With Giselle Lima • WM Announces First Quarter 2024 Earnings • Benchmark Senior Living at Hamden Assisted Living Community Named One of the Country's Best by U.S. News & World Report • God's Mighty Hand Can Uphold His Children Even Through The Hardest Times • ERVIN COHEN & JESSUP PARTNER RECOGNIZED AS TOP LAWYER IN LOS ANGELES • PONIX AWARDED $5 MILLION USDA GRANT TO BREAK "GROUND" ON CLIMATE-SMART AGRICULTURE IN GEORGIA • White House Correspondents’ Association Dinner to Welcome Hooman Shahidi, Co-founder and CEO of EVPassport, the Rapidly Gr

Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD

SAN DIEGO , March 27 /Businesswire/ - Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization.

“It is a great privilege for Cytonus to be joined by Dr. Houston, who has contributed important advances in the field of mRNA therapeutics,” said Richard Klemke, PhD., Cytonus’ cofounder and Chief Scientific Officer.

Cytonus’ Scientific Advisor Board is comprised of accomplished business leaders, distinguished research scientists, and key opinion leaders from prestigious academic institutions, immune-oncology centers, cell therapy centers and private industry.

“I am excited to join the Scientific Advisory Board of Cytonus Therapeutics and feel it's critical to advance delivery systems other than LNPs to target diseases beyond the liver,” said Dr. Houston. “Cargocytes are novel delivery vehicles which enable delivery of a variety of biological agents to a variety of tissues and organs, including tumors, the brain and fibrotic tissues.”

Dr. Houston brings over 25 years of experience as a leader in the biotech and pharmaceutical industries to Cytonus. As Chief Scientific Officer of TriLink he led teams developing new mRNA capping technologies as well as optimizing processes for making mRNA therapeutics and vaccines.

“The expertise and operational perspectives of Dr. Houston will help accelerate the realization of our shared vision for Cytonus as a new and differentiated mRNA based therapeutic company,” said Remo Moomiaie-Qajar, MD., Cytonus’ cofounder and CEO. “The field of mRNA therapeutics is currently anchored to Lipid Nano Particle usage as an approach; at Cytonus we are utilizing mRNA in a highly differentiated approach via our Cargocyte platform. Dr. Houston has been influential in the growth of the industry and TriLink and we are extremely excited to work with him to realize the next generation of mRNA therapeutics.”

Prior to TriLink, Dr. Houston was the Chief Scientific Officer at PhaseRx, where he developed mRNA-based therapeutics. He also served as Vice President of Chemistry and Formulations for Marina Biotech, where he led a team in the development of siRNA-based therapies and LNP-based delivery systems.

Dr. Houston has considerable experience in peptide-based therapeutics, as demonstrated in his role as Vice President of Preclinical Chemistry and CMC at Ascent Therapeutics. He also served as Senior Director of Chemistry and Formulations at Nastech Pharmaceutics. He received a Ph.D. in bio-organic chemistry and a B.Sc. with honors in chemistry from the University of Waterloo in Ontario, Canada.

About Cytonus Therapeutics, Inc.

Cytonus is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable "off-the-shelf" therapies.

For more information, visit www.cytonus.com and follow Cytonus on LinkedIn and on Twitter at: @CytonusTx.

Statements in this news release other than strictly historical facts, such as statements about Cytonus' plans and strategies, new and existing products, and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "aim," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.